• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Broker Upgrades And Zacks Rank #1 Status Altering The Investment Case For Chemours (CC)?

    Simply Wall St·07/26/2026 13:29:33
    Listen to the news
    • Recently, brokers have upgraded their ratings on The Chemours Company, which now carries a Zacks Rank #1, backed by forecasts for stronger earnings growth into 2026.
    • This shift in analyst sentiment highlights growing confidence in Chemours’ earnings outlook, potentially influencing how investors judge its longer-term profit recovery story.
    • Next, we’ll examine how this uptick in broker ratings could reshape Chemours’ investment narrative around earnings quality and future growth.

    The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.

    Chemours Investment Narrative Recap

    To own Chemours, you need to believe it can turn its specialty chemicals portfolio into steady, higher quality earnings while managing PFAS liabilities and TiO₂ cyclicality. The recent broker upgrades and Zacks Rank #1 lean into this recovery thesis, but they do not eliminate the near term overhang from ongoing environmental and litigation risks, which still look like the key swing factor for both earnings and cash flow.

    The recent PFAS settlement with the EPA and West Virginia regulators is particularly relevant here, because it starts to quantify part of Chemours’ long running environmental exposure. A US$22.5 million civil penalty and US$90 million in mitigation spending spread over many years help clarify some cash outflows, but they also underline that environmental compliance and remediation remain central to the investment story and to how much upside those upgraded earnings forecasts can really deliver.

    Yet behind this improving analyst sentiment, investors still need to weigh the unresolved PFAS and litigation risk that could...

    Read the full narrative on Chemours (it's free!)

    Chemours' narrative projects $6.8 billion revenue and $1.3 billion earnings by 2029.

    Uncover how Chemours' forecasts yield a $24.67 fair value, a 43% upside to its current price.

    Exploring Other Perspectives

    CC 1-Year Stock Price Chart
    CC 1-Year Stock Price Chart

    Some of the most optimistic analysts were already modeling revenues of about US$7.2 billion and earnings near US$1.4 billion by 2029, so this latest earnings upgrade story could either reinforce that upbeat view or force a rethink if PFAS and competitive risks play out differently than those projections assume.

    Explore 3 other fair value estimates on Chemours - why the stock might be worth just $24.67!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Looking For Alternative Opportunities?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.